Study reveals novel mechanism that activates KEAP1 to drive NRF2 degradation, overcoming a longstanding barrier in targeting NRF2-driven tumors The article, "A covalent allosteric molecular glue ...

Synthekine, Inc., a clinical‑stage biotechnology company developing precision cytokine therapeutics, today reported updated clinical and translational data for STK‑012 in combination with ...

(Vienna, August 9, 2022, 10:10 a.m., CEST) – Patients with metastatic non-small cell lung cancer who received a combined therapy of tremelimumab, durvalumab and chemotherapy experienced longer overall ...

An emerging concept in immunology is that rewiring of macrophage metabolism is crucial for controlling their activities. Remodelling of the TCA cycle in macrophages leads to the accumulation of ...

Targeting HER2 in combination with anti-PD-1 and chemotherapy confers a significant tumor shrinkage of gastric cancer: A multi-institutional phase Ib/II trial of first-line triplet regimen ...

STK11/LKB1 revisited: A prognostic rather than predictive biomarker for immune checkpoint inhibitor in EGFR/ALKWT nonsquamous non-small cell lung cancer (NSCLC). This is an ASCO Meeting Abstract from ...

HOUSTON - A tumor-suppressing protein snatches up an important cancer-promoting enzyme and tags it with molecules that condemn it to destruction, a research team led by scientists at The University of ...

Researchers have demonstrated that patients with metastatic non-squamous non-small cell lung cancer (NSCLC) harboring specific mutations in the STK11 and/or KEAP1 tumor suppressor genes were more ...

Study reveals novel mechanism that activates KEAP1 to drive NRF2 degradation, overcoming a longstanding barrier in targeting NRF2-driven tumors Preclinical data show antitumor activity and enhanced ...

A tumor-suppressing protein snatches up an important cancer-promoting enzyme and tags it with molecules that condemn it to destruction, a research team led by scientists at The University of Texas M.